
Aprea Therapeutics Gets Nasdaq Extension for Minimum Bid Price Compliance
Aprea Therapeutics, Inc. received a notification from Nasdaq granting an additional 180-day period, until January 19, 2027, to regain compliance with the $1.00 minimum bid price requirement. This is a second compliance period, following an initial period that ended on July 22, 2026, during which the company did not regain compliance. To meet the requirement, the common stock's closing bid price must be at least $1.00 for a minimum of 10 consecutive business days. Failure to comply by the deadline could lead to delisting.
Key Highlights
- Received Nasdaq notification on July 23, 2026.
- Granted an additional 180-day period to regain compliance.
- New compliance deadline is January 19, 2027.
- Must maintain $1.00 minimum bid price for 10 consecutive days.
- Initial compliance period ended on July 22, 2026.
Price Impact
More from APRE
Aprea Therapeutics Reports Positive Interim Data for APR-1051 Trial
Aprea Therapeutics Q3 Net Loss Widens to $4.81M; Cash Funds Operations into 2028
Aprea Therapeutics Reports Q3 2026 Results; Cash Runway to Q1 2028